{"entity":{"id":"gregory-riely","kind":"person","name":"Gregory J. Riely","aka":[],"tldr":"Lung cancer doctor who led PHAROS, the trial that brought the encorafenib and binimetinib pair to BRAF V600E-mutant lung cancer.","summary":"Gregory Riely is a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center. He was first author of the 2023 Journal of Clinical Oncology report of PHAROS, the phase 2 trial of encorafenib plus binimetinib in BRAF V600E-mutant metastatic non-small-cell lung cancer that supported the combination's approval, and has long worked on KRAS-mutant lung cancer and the clinical use of tumour genotyping.","asOf":"2026-09-18","links":[],"tags":["lung","targeted-therapy","trialist"],"related":[],"cancers":["braf-v600e-nsclc","nsclc","lung-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-pharos-encorafenib-binimetinib-riely-jco-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Thoracic medical oncologist, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["BRAF-mutant lung cancer","KRAS-mutant lung cancer","Targeted therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Riely%5BAuthor%5D"}],"papers":[{"title":"PHAROS: encorafenib plus binimetinib in BRAF V600E-mutant metastatic non-small-cell lung cancer","journal":"Journal of Clinical Oncology","year":2023,"url":"https://doi.org/10.1200/JCO.23.00774","doi":"10.1200/JCO.23.00774"}],"orcid":"0000-0001-5357-4313"},"route":"/people/gregory-riely/","neighbours":{"cancer":[{"id":"braf-v600e-nsclc","kind":"cancer","name":"BRAF V600E-mutant non-small-cell lung cancer","route":"/cancers/braf-v600e-nsclc/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"institution":[{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/"}],"paper":[{"id":"paper-yu-acquired-resistance-rebiopsy-egfr-ccr-2013","kind":"paper","name":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","route":"/key-papers/paper-yu-acquired-resistance-rebiopsy-egfr-ccr-2013/"},{"id":"paper-arbour-kras-co-mutation-outcomes-ccr-2018","kind":"paper","name":"Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer","route":"/key-papers/paper-arbour-kras-co-mutation-outcomes-ccr-2018/"},{"id":"paper-pharos-encorafenib-binimetinib-riely-jco-2023","kind":"paper","name":"PHAROS: encorafenib plus binimetinib in BRAF V600E-mutant metastatic non-small-cell lung cancer","route":"/key-papers/paper-pharos-encorafenib-binimetinib-riely-jco-2023/"},{"id":"paper-jordan-prospective-lung-adenocarcinoma-msk-cancer-discov-2017","kind":"paper","name":"Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies","route":"/key-papers/paper-jordan-prospective-lung-adenocarcinoma-msk-cancer-discov-2017/"},{"id":"paper-schoenfeld-smarca4-alterations-lung-ccr-2020","kind":"paper","name":"The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancer","route":"/key-papers/paper-schoenfeld-smarca4-alterations-lung-ccr-2020/"}]}}